Success Story: Rapid NIW Approval in 24 Days for a Cancer Biology Researcher Advancing Novel Combination Therapies
Client’s Testimonial:
“Chen Immigration handled my I-140 petition with Premium Processing smoothly and efficiently. My attorney, Ben, was responsive throughout the process, kept me informed at every stage, and made sure everything was filed correctly. The case was approved without any issues. The entire experience was so seamless that I plan on retaining Chen Immigration for my I-485 and additional services going forward. Highly recommend.”
On April 4th, 2026, we received another EB-2 NIW (National Interest Waiver) approval for a Graduate Research Assistant in the Field of Cancer Biology (Approval Notice).
General Field: Cancer Biology
Position at the Time of Case Filing: Graduate Research Assistant
Country of Origin: Pakistan
State of Residence at the Time of Filing: Massachusetts
Approval Notice Date: April 4th, 2026
Processing Time: 24 days (Premium Processing Requested)
Case Summary:
With Premium Processing at filing, the client secured an I-140 NIW approval in just 24 days. Holding a Ph.D. in cancer biology, the client focuses on developing new therapeutic strategies by combining animal models and bioinformatics to identify effective drug combinations targeting commonly mutated cancer pathways. This work directly addresses one of the most persistent challenges in oncology, namely drug resistance, and aims to expand treatment options for patients with difficult-to-treat cancers.
The client’s proposed endeavor centers on integrating experimental and computational approaches to uncover synergistic drug combinations. By leveraging animal models to study disease mechanisms and applying bioinformatics to analyze mutation-driven pathways, the research contributes to precision oncology and the development of more effective, mechanism-based therapies. Given the high mortality associated with drug-resistant cancers and the growing national burden of cancer care, this work aligns closely with U.S. public health priorities and the demand for innovative treatment strategies.
The client’s record of achievement reflects both originality and growing influence in the field:
- 4 peer-reviewed journal articles, including 1 co-first-authored paper accepted for publication
- 4 conference abstracts, with 2 first-authored
- 76 total citations
Rather than being viewed as standalone numbers, these metrics demonstrate independent reliance by other researchers. Citation activity indicates that peers are actively building upon the client’s findings, while publication in selective venues confirms that the work has passed rigorous expert evaluation.
In addition, the client has completed at least 10 peer reviews. This role is reserved for researchers trusted to evaluate the work of others, serving as a clear signal of recognized expertise and professional credibility.
Further strengthening the case, the client’s research has received support from major U.S. funding bodies, including multiple institutes within the National Institutes of Health (NIH), the National Science Foundation (NSF), and other federal and research organizations. Such funding is highly selective and reflects alignment with nationally significant scientific priorities, reinforcing both the merit and broader impact of the work.
The petition included 4 recommendation letters from experts in the field. These letters emphasized the client’s innovative use of interdisciplinary methods and the practical relevance of the research to advancing cancer treatment.
The swift approval highlights how a focused narrative, supported by objective indicators of originality, independent reliance, and peer trust, can present a compelling argument for a National Interest Waiver. The client is now well-positioned to continue contributing to the development of more effective cancer therapies in the United States.